1Fuster V. Epidemic of cardiovascular disease and stroke: the three main challenges [ J ]. Circulation, 1999, 99 : 1132-1137.
2David M Herrington, David M Reboussin, Penny C Sharp.The Estrogen Replacement and Atherosclerosis (ERA)Study: study design and baseline characteristics of the cohort[J]. Controlled Clinical Trials, 2000,21 : 257-285.
3Adams M R, Register T C, Golden D L, et al. Medroxyprogesterone acetate antagonizes inhibitory effects of conjugated equine estrogens on coronary artery atherosclerosis [J].Arterioscler Thromb Vasc Biol, 1997, 17:217-221.
4Paola Albertazzi, Raffaele Di Micco, Ettore Zanardi. Tibolone: a review[J]. Maturitas, 1998, 30:295-305.
5C Egarter, M Sator, P Berghammer, et al. Efficacy, tolerability, and rare side effects of tibolone treatment in postemenopausal women [J]. International Journal of Gynecology & Obstetrics, 1999, 64 : 281-286.
6Ingrid B Meeuwsen, Monique M Samson, Sijmen A Duursma,et al. The influence of tibolone on quality of life in postmenopausal women[J]. Maturitas, 2002, 41:35-43.
7Mohammed H Moghadasian. Experimental atherosclerosis: A historical overview[J]. Life Sciences, 2002, 70:855-865.
8A Sanjuan, C Castelo-Branco, M Colodron, et al. Effects of estradiol, cyproterone acetate, tibolone and raloxifene on uterus and aorta atherosclerosis in oophorectomized cholesterol-fed rabbits[J]. Maturitas, 2003, 45:59-66.
9Andberg P, Peters J L, Demacker P N, et al. Tibolone prevents atherosclerotic lesion formation in cholesterol-fed,ovariectomized rabbits [J]. Arterioscler Thromb Vasc Biol,1998, 18:1844-1854.
10Annapaula Giuliettil, Lut Overberghl, Dirk Valckx, et al.An overview of real-time quantitative PCR: applications to quantify cytokine gene expression [J]. Methods, 2001, 25:386-401.
二级参考文献5
1罗邦尧，Diagnosis and Therapy of Adrenal Desease，1995年，9页
1Craven TE, Ryu JE, Espeland MA, et al. Evaluation of the association between carotid artery atherosclerosis and coronary stenosis a case control study [ J ]. Circulation, 1990,82 ( 1 ) : 1230 - 1235.
2Kuh D, Langenberg C, Hardy R,et al. Cardiovascular risk at age 53 years in relation to the menopause transition and use of hormone replacement therapy:a prospective British birth cohort study[ J ]. B JOG, 2005,112(4) :476 -485.
